AdaptHealth Corp. (AHCO) Balance Sheet

The sequential decline in total assets, from $4.5B in 2024Q1 to $4.3B in 2026Q2, appears driven by asset sales and impairments, notably the divestiture of the Diabetes business. Debt has remained elevated, with D/E climbing from 1.35 to 1.49 over the same period, suggesting that deleveraging has not kept pace with asset reductions. This trajectory implies a balance sheet that is becoming more leveraged relative to its shrinking asset base, which may heighten financial risk if cash flows deteriorate further.

Despite a modest reduction in absolute debt from $2.3B in 2024Q1 to $2.1B in 2026Q2, the D/E ratio has increased from 1.59 to 1.49, reflecting a shrinking equity base. The company's negative retained earnings of -$782.9M and persistent net losses suggest that debt is not being serviced through internal profitability, which may indicate necessity-driven borrowing. With cash reserves of only $43.3M, the company appears vulnerable to refinancing risk if credit markets tighten, especially given the negative net margin.

The asset mix is heavily weighted toward goodwill, which at $2.4B is more than half of total assets, reflecting the company's roll-up strategy. This concentration poses a significant impairment risk, especially given the recent divestiture and flat revenue growth, which may indicate that acquired synergies are not materializing. PPE has increased from $618.4M to $828.4M, suggesting continued investment in rental equipment, but the negative net margin implies that these assets are not yet generating adequate returns.

The equity base has contracted from $1.5B to $1.4B over the past year, driven by persistent net losses that have pushed retained earnings deeper into negative territory. This trend indicates that the company is not generating sufficient profits to sustain its equity, and the negative ROE of -4.6% suggests that shareholder capital is being destroyed. The lack of share repurchases or dividends, as noted in the cash flow analysis, implies that management is conserving cash for debt service and acquisitions, but the equity quality remains weak.

The current ratio has deteriorated from 1.33 in 2024Q1 to 1.12 in 2026Q2, indicating a shrinking cushion of current assets over current liabilities. Cash reserves have declined from $109.7M to $43.3M over the same period, which, combined with negative free cash flow in recent quarters, suggests that the company may struggle to meet near-term obligations without additional financing. This thin liquidity position, coupled with high debt, implies that the company has limited buffer against operational shocks or reimbursement delays.